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The sarcoplasmic reticulum Ca2+-ATPase (SERCA) isoforms are normally expressed in coordina-
tion with the corresponding myosin heavy chain (MyHC) isoforms in the fibers of skeletal mus-
cle but this coordination is often disrupted in pathological conditions. In the streptozotocin-in-
duced diabetes of rats (stz-rats), the soleus muscle showed peripheral neuropathy and the SER-
CA2a level decreased in type I (slow-oxidative) fibers compared to the control muscles, whereas 
the expression of the corresponding slow MyHC1 did not change. No difference was found at 
the mRNA and protein levels of SERCA and MyHC isoforms in the whole soleus, except that 
the level of the SERCA2a protein specifically declined in stz-rats compared to the controls. This 
shows that the coordinated expression of SERCA2a and MyHC1 is disrupted at the SERCA2a 
protein level in the diabetic soleus. The results are in line with previous observations that regu-
lators of the Ca-homeostasis may adapt faster to type I diabetes than the contractile elements.
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INTRoduCTIoN
Skeletal muscle is a major target of insulin. 
Decline of insulin level observed in type I diabetes 
restricts glucose uptake and severely affects metabo-
lism, function and morphology of muscle (Klueber & 
Feczko, 1994; Aughsteen et al., 2006; reviewed by Sun 
et al., 2008). In a rodent model of type I diabetes, hy-
perglycemia is induced by streptozotocin (streptozo-
cin), a fungal toxin damaging the insulin-producing 
pancreatic beta-cells (reviewed in Szkudelski, 2001). 
Rats with streptozotocin-induced diabetes (stz-rats) 
develop peripheral neuropathy (Klueber & Feczko, 
1994; Snow et al., 2005) and a slow-to-fast transition 
of fiber types in the soleus (Punkt et al., 1999; Snow 
et al., 2005). The conversion from slow to fast muscle 
phenotype declines the level of slow myosin heavy 
chain (MyHC1) and increases the levels of fast my-
osins (MyHC2a, MyHC2x and MyHC2b) (Pette & 
Staron, 2000). Myosin is responsible for muscle con-
traction and the sarcoplasmic/endoplasmic reticulum 
Ca2+-ATPase (SERCA) for relaxation, therefore the 
coordinated expression of the corresponding MyHC 
and SERCA isoforms is functionally relevant and 
characteristic to the fiber types of normal muscle. 
The slow SERCA2a is coexpressed with the MyHC1 
isoform in the type I (slow-oxidative) fibers. The fast 
type SERCA1a isoform is expressed together with 
MyHC2a, MyHC2x and MyHC2b in the type IIA, 
IIx/d and IIb (from fast-oxidative to fast-glycolytic) 
fibers, respectively (Talmadge et al., 1996; Mendler et 
al., 1998; Zador et al., 2007). In spite of the coordinat-
ed expressions, current research has shown that fac-
tors controlling the levels of myosins and SERCAs 
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are different in both normal and pathological con-
ditions (Zador & Wuytack, 2003; Zador et al., 2005; 
Talmadge & Paalani, 2007; Szabo et al., 2008). 
Regulators of the Ca2+ homeostasis respond 
relatively rapidly to blood glucose level in skeletal 
muscle. The calcineurin-NFAT pathway is down-
regulated, and the DNA binding of NFAT (nuclear 
factor of activated T-cells) and MEF-2 (muscle en-
hancing factor-2) is lower in rat skeletal muscle 
three weeks after streptozocin treatment (Costelli et 
al., 2007). Insulin receptor substrate 1 and 2 (IRS-1 
and IRS-2) increases binding to SERCA1 and SER-
CA2 in normoglycemic rat after insulin stimulation 
and phosphorylation by insulin receptor kinase (Al-
genstaedt et al., 1997). This suggests that SERCAs 
are targets of insulin action and hints at a direct 
link between the insulin-dependent and Ca2+-signal-
ing pathways. The MyHC1 level decreases in the rat 
soleus at 2–3 months after streptozotocin treatment 
(Punkt et al., 1999; Snow et al., 2005), but no paral-
lel detection of MyHC and SERCA isoforms has 
been presented in the same diabetic muscle. Here 
we monitored SERCA together with MyHC at the 
mRNA and protein levels in the same soleus mus-
cles of stz-rats four weeks after streptozocin treat-
ment, in order to describe the extent of their coex-
pression. 
MATERIAlS ANd METHodS
Animals and treatments. Experiments 
were performed on 4-week-old male Wistar rats 
(weighing 170 ± 40 g). Rats were housed at a 
constant temperature (20oC), humidity, 12 h light-
dark cycle, and were allowed free access to standard 
chow and water. All experimental protocols were 
in accordance with the guidelines of the Committee 
on the Care and Use of Laboratory Animals of 
the Council on Animal Care at the Semmelweis 
University of Budapest, Hungary (TUKEB 99/94). 
Rats were rendered diabetic with streptozotocin (65 
mg/kg i.v., Sigma Chemical Co.) dissolved in 0.1 M 
citrate buffer (pH 4.5). Only streptozocin-treated 
animals with plasma glucose concentrations above 
15 mmol/l were considered diabetic and included 
in the study. Vehicle-treated rats served as controls. 
Four weeks after the induction of DM (defined as 
day 0) the animals were anaesthetized (40 mg/kg 
pentobarbital sodium, Abbott Laboratories) and 
sacrified by decapitation. Muscles, blood and post 
mortem urinary samples were collected for further 
investigations. The soleus muscles were dissected 
and frozen in isopentane cooled in liquid nitrogen 
and stored at –80oC. Non-fasting serum glucose 
concentration was measured using a kit from Roche 
Diagnostics, Ltd.
RT-PCR. Total RNA was extracted by 
AGPC-method and the specific mRNA levels were 
determined by RT-PCR as described (Zádor et al., 
1996; Fenyvesi et al., 2004). The extracted RNA was 
measured at 260 nm and reverse transcription was 
made on 1 µg RNA using oligo (dT) primers. The 
proportion of SERCA1 and SERCA2 PCR fragments 
was measured by ratio RT-PCR according to the 
method detailed in (Zador et al., 1996). Shortly, the 
same primers were used to amplify cDNA of both 
SERCA1 and SERCA2 in one PCR mix. The resulted 
amplification was divided into aliquots which were 
digested with either StyI (hydrolysing SERCA1) 
or Trpu9I (hydrolysing SERCA2) and a control 
digestion with both restriction enzymes was also 
applied. The digested aliquots were loaded onto 
6% polyacrylamide gel. The ratio of the SERCA 
transcripts was estimated from the level of the 
undigested fragments of the different restriction 
enzyme reactions. The fragments were stained with 
ethidium bromide and quantified by Gel Doc 2000 
(Bio-Rad Laboratories; Hercules, CA, USA) and 
Quantity One software. The level of other mRNAs 
was estimated by relative RT-PCR method described 
earlier (Fenyvesi et al., 2004). All PCR amplifications 
were checked to be in the linear range. 
Immunostaining, morphometry and 
immunoblotting. Frozen sections were taken from 
the central part of the muscles and immunostained 
as described in (Zádor et al., 1998). Primary 
antibodies to MyHC1 (BA-D5, mouse, 1 : 50; 
Schiaffino et al., 1989), MyHC2a (SC-71, mouse, 1:20; 
Schiaffino et al., 1989), SERCA1 (A3, mouse, 1 : 20; 
Zubrzycka-Gaarn et al., 1984) and SERCA2a (R-15; 
rabbit, 1 : 400; Wuytack et al., 1989) were used and 
immunohybridizations were detected with HRP-
conjugated anti-mouse or anti-rabbit antibodies 
and peroxidase histochemistry. The fiber size (cross 
sectional area, CSA) was measured by Cell software 
(Olympus Soft Imaging Solution GmbH, Münster) at 
least for 100 fibers from each muscle. 
The SERCA and MyHC isoforms were isolated 
from the same muscle and measured by immunoblotting 
as detailed in (Zádor & Wuytack, 2003; Szabó et al., 
2008). Shortly, the muscles were homogenized in 
2.5 ml of 20% sucrose, 5 mM Hepes (pH 7.5) and 
proteinase inhibitor cocktail (Roche) in the cold room. 
The homogenate was centrifuged at 1 000 × g for 10 min. 
The supernatant was further centrifuged at 200 000 × g 
for 30 min to sediment the mitochondrial+microsomal 
fraction for SERCA isolation (Zádor et al., 1998). The 
pellet of the 1 000 × g centrifugation was subjected to 
myosin extraction (Hämalainen & Pette, 1997). The 
protein content of the crude homogenate and the end 
fractions of the isolations was measured by the BCA 
method. Gel loading was controlled after blotting onto 
PVDF membrane (Immobilon-P, Millipore) by Ponceau 
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staining. The membranes were hybridized with MyHC 
and SERCA antibodies, then with HRP-conjugated 2nd 
antibodies and developed with Ni-DAB (Wuytack et 
al., 1994). The immunoblots were quantified by Gel 
Doc 2000 (Bio-Rad Laboratories; Hercules, CA, USA) 
and Quantity One software.
Statistics. Unpaired t-test was used to find 
significant differences, 2–4 animals were used for 
the mRNA studies, 3–4 animals for the immunoblots 
and 3 animals for the immunohistochemistry at least 
one hundred fibers were inspected for fiber types 
from each muscle.
RESulTS
Immunohistochemistry of streptozotocin-(streptozo-
cin) treated rat soleus muscles
The weight and protein content of soleus of 
stz-rats was not significantly different compared 
to the controls (Table 1). However, the fiber size 
(cross sectional area, CSA) was 83% of that of the 
control muscles (2912    ± 89 vs. 3521 ± 91 μm2, P < 0.01, 
n = 3). The percentage of type I fibers expressing 
myosin heavy chain (MyHC1) showed a tendency 
to decline but it was not statistically different from 
that of the controls (73.5 ± 3.1 vs. 80.9 ± 1.6%, P =  0.128, 
n=3). The ratio of type IIA fibers expressing myosin 
heavy chain 2a (MyHC2a) was also not significantly 
different in streptozocin-soleus compared to the 
control (26.9 ± 3.% vs. 19.5 ± 1.6%, P = 0.095, n = 3). 
The number of hybrid fibers expressing both 
MyHC1 and MyHC2a was about the same in the so-
leus of diabetic and controls rats (Table 1). However, 
in stz-rats the percentage of associated type IIA 
fibers (two or more fibers together) was higher 
than in the controls (57 ± 4.3 vs. 28.6 ± 5, P<0.05). This 
indicated peripheral neuropathy and a higher rate 
of reinnervation in the streptozocin-treated soleus 
than in the control muscles (Karpati & Engel, 1968; 
Jaweed et al., 1975).
The MyHC isoforms are the most frequently 
used but not the only markers of muscle fiber types 
(Sciaffino & Reggiani, 1996). The sarcoplasmic/endo-
plasmic reticulum Ca2+-ATPase (SERCA) isoforms 
are expressed in coordination with the corresponding 
MyHCs and can also be used for fiber typing 
(Talmadge et al., 1996). We immunostained the 
muscle fibers on consecutive sections for SERCA2a 
and SERCA1 in addition to the MyHC1 and MyHC2a 
isoforms (Fig. 1). In adult soleus, SERCA1a practically 
accounted for the total amount of SERCA1 (Zádor et 
al., 2007) and it was specifically expressed in the type 
IIA fibers, whereas SERCA2a was present exclusively 
in type I fibers. In the diabetic muscles, SERCA1a was 
stained in type IIA fibers with similar intensity as in 
the control, but SERCA2a expression in type I fibers 
was practically not different from the background 
level found in the type IIA fibers. Therefore we 
aimed to measure the difference at the mRNA and 
protein levels of the SERCA and MyHC isoforms in 
the whole soleus muscle.
Table 1. Morphological parameters of diabetic and con-
trol rat soleus muscles.
1Measured from the first homogenate; 2two or more ad-
jacent fibers, *P<0.05, **P<0.01, mean  ± S.E., n=4 for the 
weight and protein content and n=3 for the fiber param-
eters.
Parameter Diabetic Control
Weight (mg) 157 ± 9 162 ± 7
Protein content (mg)1 34.4 ± 3 31.9 ± 2
Fiber CSA (μm2) 2912 ± 89** 3521 ± 91
Type I fibers (%) 73.5 ± 3.1 80.9 ± 1.6
Type IIA fibers (%) 26.9 ± 3 19.5 ± 1.6
Hybrid fibers (%) 0.5 ± 0.2 0.4 ± 0.1
% of IIA fibers in association2 57 ± 4.3* 28.6 ± 5
Figure 1. Myosin and SERCA isoforms in fibers of so-
leus muscle of stz-rats.
Immunostaining was made on parallel sections. Please 
note coexpression of MyHC1 with SERCA2a in type I fib-
ers and coexpression of MyHC2a with SERCA1 in type 
IIA fibers of control and stz-rats. Expression of SERCA2a 
is practically not distinguishable in type I and type IIA 
fibers in stz-rats unlike in the control, suggesting lower 
level of the Ca2+ pump. *Indicate identical positions on 
sections. Bar is 100 μm.
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 mRNA levels of MyHC and SERCA isoforms
The level of GAPDH mRNA was not different 
in streptozocin-soleus compared to the controls (Fig. 
2A), therefore we used it as an RT-PCR control, 
reference mRNA. Normalized levels of SERCA1a 
and SERCA2a mRNAs were not significantly lower 
in the soleus of stz-rats than in the controls (Fig. 
2B). Neither were the relative levels of SERCA1 and 
SERCA2 transcripts, measured by ratio-RT-PCR, 
different in the diabetic and control soleus (see 
right-hand columns in Fig. 2B and representative 
gel in Fig. 2C). Similarly, there were no significant 
differences in the MyHC1 and MyHC2a mRNA 
levels of soleus muscles of the streptozocin-treated 
and control rats. 
Protein levels of MyHC and SERCA isoforms
In accordance with the mRNA levels, the 
MyHC1, MyHC2a and SERCA1 protein levels 
were not different on immunoblots of the soleus 
of streptozocin-treated and control rats (Fig. 3). 
However, the SERCA2a level was about 50% lower 
(P = 0.0002) in the soleus of streptozocin-treated 
rats compared to that of the controls. This was in 
agreement with the observation made on transverse 
sections that the SERCA2a level was decreased in 
type I fibers of the soleus of stz-rats.
dISCuSSIoN
The soleus muscle of stz-rats showed similar 
weight and protein content but a smaller fiber size 
than the control. In another model, the selectively 
denervated soleus, a similar decrease in fiber size 
but not in fresh weight or protein content has been 
reported after 3 days, while both fresh weight and 
protein content decreased with fibers size after 
7 days (Szabó et al., 2008). This shows that fiber size 
reflects muscle atrophy earlier than the fresh weight 
or protein content. 
An increased association of type IIA (fast-
oxidative) fibers is an indication of peripheral 
neuropathy (Karpati & Engel, 1968; Jaweed et al., 
1975), and it also appears to be an early marker of 
diabetes in streptozocin-soleus (Snow et al., 2005). 
Parallel with fiber type association, we detected a 
tendency but not a significant transition of slow 
to fast fiber types at four weeks after streptozocin 
treatment. We used only three animals for this 
experiment, but increasing the sample size above 
n=14 in both groups should result in a significant dif-
Figure 2. Myosin and SERCA mRNA levels in soleus of 
stz-diabetic rats.
(A) GAPDH mRNA levels used for normalization. (B) 
mRNA levels in percent of control (mean  ± S.E., n = 3–4). 
Above columns representative bands of RT PCR are 
shown. (C) The ratio of SERCA1/2 mRNA levels (mean 
± S.E., n = 3 for the control and n = 2 for the stz-diabetic 
rats) Left. Representative gels of ratio-RT PCR analysis of 
SERCA1 and SERCA2 (right). Undigested SERCA isofor-
ms are indicated above lanes. Only the upper undigested 
bands (indicated by small arrows) were used for quantita-
tion; c, control; stz, streptozotocin-treated.
Figure 3. MyHC and SERCA protein levels in soleus of 
stz-rats.
Above columns representative bands of immunoblots are 
shown. ***P < 0.001, n = 3–4. Other symbols as in Fig. 2.
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ference of fiber types according to a power analysis 
of our data (S.D. and mean difference). This was in 
agreement with Rutschmann et al. (1984) who also 
reported no decline of slow myosin level after the 
same duration (4 weeks) in stz-rats, in contrast to 
reports of lower slow myosin levels and significant 
slow-to-fast fiber type transition at 2–3 months after 
streptozocin treatment (Punkt et al., 1999; Snow et al., 
2005). The above studies all used n ≤ 8 rats per group. 
The range of streptozotocin doses used for inducing 
type I diabetes in rat is relatively narrow (reviewed 
by Szkudelski, 2001), therefore the variance in the 
fiber type shift is more likely due to the duration of 
hyperglycemia than to the applied amount of the to-
xin. 
According to the unchanged ratio of myosin 
and SERCA1a in fiber types, the streptozocin-soleus 
showed similar MyHC1, MyHC2a and SERCA1a 
mRNA and protein levels compared to those of the 
control. The lower expression level of SERCA2a in 
diabetic soleus type I fibers was supported by the 
immunoblotting data but not the RT-PCR results. 
This shows that different mechanisms dysregulate 
the levels of the SERCA2a pump and the slow 
myosin in the streptozocin-soleus than in the 
denervated soleus, because, in the latter one, the 
dysregulation occurred both at the mRNA and pro-
tein levels (Szabó et al., 2008). 
The SERCA2a protein level may decrease 
in several ways (reviewed by Vangheluwe et al. 
2005). In diabetic rat heart, it declines because of an 
increased level of glycosylation (Bidasee et al., 2004). 
Advanced glycation end products also accumulate 
in the skeletal muscle of diabetic animals (Snow et 
al., 2006). Although the levels of both SERCA2a and 
its inhibitor phospholamban decrease in diabetes, 
the phospholamban/SERCA2a ratio becomes higher 
(Rupp et al., 1989; Belke et al., 2004; Bidasee et al., 
2004; Vasanji et al., 2004). The levels of reactive 
oxygen and nitrogen species (ROS and RNS) are 
elevated (Aragno et al., 2004; Mastrocola et al., 2008) 
and they decrease the levels of specific proteins like 
SERCA2a (Aragno et al., 2004; Mastrocola et al., 2008; 
reviewed by Vangheluwe et al., 2005). 
Both SERCA1 and SERCA2 isoforms interact 
with phosphorylated forms of insulin receptor 
substrates, IRS-1 and IRS-2 (Algenstaedt et al., 1997). 
This interaction can be stimulated by insulin in the 
control but not in stz-rats (Algenstaedt et al., 1997). 
It is an interesting question whether the decreased 
interaction of IRS and SERCA in streptozocin-
diabetic rats (Algenstaedt et al., 1997) is related to 
the decline of SERCA2a level reported here.
The pathological mechanism of diabetes 
involves inhibition of phosphatidylinositol 3-kinase 
(PI3-K) (Lee et al., 2004). Low activity of the PI3-
K/Akt pathway in the endothelium and/or skeletal 
muscle may contribute to defective signals and 
subsequent catabolism (reviewed by Kobayashi et 
al., 2005). However, a direct role of this pathway in 
the phosphorylation of SERCA2a or its regulator, 
phospholamban, has not been documented yet.
The expression of SERCA2 isoforms is largely 
regulated at the level of RNA splicing in the normal 
heart and slow skeletal muscle, i.e. the structure of 
the 3’ end confers higher stability on SERCA2a than 
on SERCA2b mRNA (reviewed by Misquita et al., 
2006). However, no such mechanism was implicated 
in the diabetic soleus (in our experiments) or in the 
diabetic heart (Bidasee et al., 2004), since the SER-
CA2a mRNA level was not different from that of the 
control. The splicing of SERCA1, SERCA2 and the 
muscle-specific insulin receptor are each regulated 
by muscleblind protein 1 (MLNB1) (Savkur et al., 
2001; Ho et al., 2004; Hino et al., 2007) but no such 
regulation was implicated in the streptozocin-soleus. 
The calcineurin-NFAT pathway is a key factor 
of muscle remodeling (reviewed by Bassel-Duby 
& Olson, 2006) and it has been reported to decline 
in streptozocin-induced diabetic rats parallel with 
muscle atrophy (Costelli et al., 2007). Conclusively, 
muscle specific overexpression of calcineurin 
improves insulin action and glucose metabolism 
in the soleus of transgenic mice (Ryder et al., 2003; 
Long et al., 2007). Since SERCA2a is the major pump 
regulating the level of Ca2+ in the sarcoplasm, it is an 
interesting question how the decrease of SERCA2a 
level reported here is related to the decline of the 
calcineurin-NFAT pathway in diabetic muscle. 
In conclusion, we suggest that the SERCA2a 
protein level is an earlier marker than that of 
MyHC1 for muscle diabetes. This implicates that 
the Ca2+ metabolism reacts more readily to diabetic 
stress than do the contractile elements. The separate 
regulation of SERCA2a and MyHC1 is a further 
suport of this conjecture.
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